ARTICLES SCIENTIFIQUES SUR LE CANCER DU SEIN

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève

D.Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.PMID: 30089825 Free PMC article.

 

Reply: Minimally Invasive Laparoscopically Dissected Deep Inferior Epigastric Artery Perforator Flap: An Anatomical Feasibility Study and a First Clinical Case.

Benjoar MD, Berdah Y, Dubosq F, Zarca D, Lantieri L, Hans S, Hivelin M.

Plast Reconstr Surg. 2018 Nov;142(5):787e-789e. doi: 10.1097/PRS.0000000000004947.PMID: 30512000

​

Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?

Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R.

Eur J Surg Oncol. 2016 Aug 31. pii: S0748-7983(16)30857-5. doi: 10.1016/j.ejso.2016.08.012. [Epub ahead of print]

​

Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.

Torres-Roca JF, Fulp WJ, Caudell JJ, Servant N, Bollet MA, van de Vijver M, Naghavi AO, Harris EE, Eschrich SA.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):631-8. doi: 10.1016/j.ijrobp.2015.06.021. Epub 2015 Jun 25.

​

Comparison between two different algorithms used for pretreatment QA via aSi portal images.

Merheb C, Chevillard C, Ksouri W, Fawzi M, Bollet M, Toledano A.

J Appl Clin Med Phys. 2015 May 8;16(3):5202. doi: 10.1120/jacmp.v16i3.5202.

 

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.

Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM.

Br J Radiol. 2015 Apr;88(1048):20140800. doi: 10.1259/bjr.20140800. Epub 2015 Feb 3.

​

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Bougnoux P, Denis F, Bollet M, Dendale R, Vago NA, Campana F, Fourquet A, Kirova YM.

Breast. 2014 Dec;23(6):816-20. doi: 10.1016/j.breast.2014.08.015. Epub 2014 Sep 26.

​

Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL).

Blanchard D, Bollet M, Dreyer C, Binczak M, Calmels P, Couturaud C, Espitalier F, Navez M, Perrichon C, Testelin S, Albert S, Morinière S; SFORL Work Group.

Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Sep;131(4):253-6. doi: 10.1016/j.anorl.2014.07.001. Epub 2014 Aug 4.

​

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.

Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F.

Br J Cancer. 2014 Apr 29;110(9):2195-200. doi: 10.1038/bjc.2014.143. Epub 2014 Apr 8.

​

Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.

Guillot E, Vaysse C, Goetgeluck J, Falcou MC, Couturaud B, Fitoussi A, Fourchotte V, Laki F, Malhaire C, Sigal-Zafrani B, Sastre-Garau X, Bollet MA, Mosseri V, Reyal F.

Breast. 2014 Apr;23(2):97-103. doi: 10.1016/j.breast.2013.12.002. Epub 2013 Dec 31.

​

Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.

Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.

Int J Cancer. 2013 Dec 15;133(12):2834-42. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.

 

Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.

Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, Fourchotte V, Laki F, Alran S, Asselain B, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X.

PLoS One. 2013;8(3):e55901. doi: 10.1371/journal.pone.0055901. Epub 2013 Mar 19.

​

Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].

Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, Campana F, Bollet MA, Fourquet A, Kirova YM.

Cancer Radiother. 2013 Jun;17(3):183-90. doi: 10.1016/j.canrad.2012.12.006. Epub 2013 Mar 15. French.

​

Infiltrating lobular breast cancer: truly a separate entity! Consequences for radiation therapy.

Poortmans PM, Bollet M, Van Limbergen E.

Radiother Oncol. 2013 Jan;106(1):1-4. doi: 10.1016/j.radonc.2012.12.010. Epub 2013 Jan 22.

​

[A case of cutaneous mammary re-irradiation].

Jacob J, Pierga JY, Fourchotte V, Kirova YM, Bollet MA.

Cancer Radiother. 2012 Oct;16(7):638-40. doi: 10.1016/j.canrad.2012.08.002. Epub 2012 Oct 23. French.

 

Adjuvant radiotherapy in the management of axillary node negative invasive breast cancer: a qualitative systematic review.

Bourgier C, Aimard L, Bodez V, Bollet MA, Cutuli B, Franck D, Hennequin C, Kirova YM, Azria D.

Crit Rev Oncol Hematol. 2013 Apr;86(1):33-41. doi: 10.1016/j.critrevonc.2012.09.010. Epub 2012 Oct 22. Review.

​

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.

Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.

​

Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.

Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, De Cremoux P, Fourquet A, Kirova YM.

World J Radiol. 2012 Jul 28;4(7):318-23. doi: 10.4329/wjr.v4.i7.318.

​

New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.

Cacheux W, Bollet MA, Servois V, Zefkili S, Farkhondeh F, Baranger B, Mariani P.

Med Oncol. 2012 Dec;29(5):3143-6. doi: 10.1007/s12032-012-0311-z. Epub 2012 Aug 2.

​

Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer.

Marchand V, Angelergues A, Gobaux V, Hajage D, Kirova YM, Campana F, Dendale R, Reyal F, Pierga JY, Fourquet A, Bollet MA.

Am J Clin Oncol. 2013 Oct;36(5):425-9. doi: 10.1097/COC.0b013e31825466a6.

​

Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.

Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X.

PLoS One. 2012;7(4):e35184. doi: 10.1371/journal.pone.0035184. Epub 2012 Apr 18. Erratum in: PLoS One. 2012;7(7). doi: 10.1371/annotation/46dc7048-61b1-45bd-b4cd-a3b80a2f3f5a.

​

[Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma].

Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA.

Cancer Radiother. 2012 Apr;16(2):128-35. doi: 10.1016/j.canrad.2011.10.013. Epub 2012 Feb 15. French.

​

Search for a gene expression signature of breast cancer local recurrence in young women.

Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ.

Clin Cancer Res. 2012 Mar 15;18(6):1704-15. doi: 10.1158/1078-0432.CCR-11-1954. Epub 2012 Jan 23.

 

External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.

Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, Pierga JY, Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal-Zafrani B, Senechal C, Asselain B, Sastre X, Reyal F.

PLoS One. 2011;6(11):e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.

​

Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial.

Bollet MA, Belin L, Reyal F, Campana F, Dendale R, Kirova YM, Thibault F, Diéras V, Sigal-Zafrani B, Fourquet A.

Radiother Oncol. 2012 Jan;102(1):82-8. doi: 10.1016/j.radonc.2011.08.017. Epub 2011 Sep 8.

​

[Role of locoregional radiation therapy in breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. The Institut Curie-Hôpital René-Huguenin experience].

Le Scodan R, Bruant S, Selz J, Bollet MA, Daveau C, de la Lande B, Lerebours F, Labib A, Stevens D.

Cancer Radiother. 2011 Dec;15(8):675-82. doi: 10.1016/j.canrad.2011.04.004. Epub 2011 Aug 9. French.

​

[Management of inflammatory breast cancer after neo-adjuvant chemotherapy].

Abrous-Anane S, Savignoni A, Daveau C, Pierga JY, Gautier C, Reyal F, Dendale R, Campana F, Kirova Y, Fourquet A, Bollet MA.

Cancer Radiother. 2011 Dec;15(8):654-62. doi: 10.1016/j.canrad.2011.01.009. Epub 2011 Aug 5. French.

​

The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.

Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y.

PLoS One. 2011;6(5):e20297. doi: 10.1371/journal.pone.0020297. Epub 2011 May 31.

​

Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy.

Chira C, Jacob J, Derhem N, Bollet MA, Campana F, Marchand V, Pierga JY, Fourquet A, Kirova YM.

J Neurooncol. 2011 Nov;105(2):401-8. doi: 10.1007/s11060-011-0607-4. Epub 2011 Jun 5.

​

Can we decrease the skin reaction in breast cancer patients using hyaluronic acid during radiation therapy? Results of phase III randomised trial.

Kirova YM, Fromantin I, De Rycke Y, Fourquet A, Morvan E, Padiglione S, Falcou MC, Campana F, Bollet MA.

Radiother Oncol. 2011 Aug;100(2):205-9. doi: 10.1016/j.radonc.2011.05.014. Epub 2011 May 31.

​

Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.

Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e145-52. doi: 10.1016/j.ijrobp.2011.03.013. Epub 2011 May 24.

​

[Concurrent whole-brain radiotherapy with trastuzumab for treatment of brain metastases in breast cancer patients: questions and answers].

Riahi Idrissi H, Chargari C, Bollet MA, Le Scodan R, Olivier L, Dorval T, Marchand V, Cottu P, Dieras V, Campana F, Fourquet A, Kirova YM.

Bull Cancer. 2011 Apr;98(4):425-32. doi: 10.1684/bdc.2011.1342. Review. French.

​

[Radiotherapy for breast cancer and pacemaker].

Menard J, Campana F, Kirov KM, Bollet MA, Dendale R, Fournier-Bidoz N, Marchand V, Mazal A, Estève M, Fourquet A, Kirova YM.

Cancer Radiother. 2011 Jun;15(3):197-201. doi: 10.1016/j.canrad.2010.11.014. Epub 2011 Mar 21. French.

 

High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis.

Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, Quintin E, Hayem G, Palazzo E, Meyer O, Chollet-Martin S, Dieudé P.

J Rheumatol. 2011 Jun;38(6):979-82. doi: 10.3899/jrheum.101261. Epub 2011 Mar 1.

​

Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy.

Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, Lerebours F, Labib A, Bruant S.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e1-7. doi: 10.1016/j.ijrobp.2010.12.054. Epub 2011 Mar 4.

 

Management of phyllodes breast tumors.

Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, Bollet M, Pierga JY, Salmon R, Fitoussi A; Breast Cancer Study Group of the Institut Curie.

Breast J. 2011 Mar-Apr;17(2):129-37. doi: 10.1111/j.1524-4741.2010.01045.x. Epub 2011 Jan 19.

 

[Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?].

Daveau C, Savignoni A, Abrous-Anane S, Pierga JY, Reyal F, Gautier C, Kirova YM, Dendale R, Campana F, Fourquet A, Bollet MA.

Cancer Radiother. 2011 Apr;15(2):106-14. doi: 10.1016/j.canrad.2010.06.020. Epub 2010 Nov 16. French.

 

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.

Chargari C, Idrissi HR, Pierga JY, Bollet MA, Diéras V, Campana F, Cottu P, Fourquet A, Kirova YM.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):631-6. doi: 10.1016/j.ijrobp.2010.06.057. Epub 2010 Oct 6.

​

Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

Chargari C, Kirov KM, Bollet MA, Magné N, Védrine L, Cremades S, Beuzeboc P, Fourquet A, Kirova YM.

Cancer Treat Rev. 2011 Jun;37(4):321-30. doi: 10.1016/j.ctrv.2010.08.007. Epub 2010 Sep 22. Review.

​

The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.

Caussa L, Kirova YM, Gault N, Pierga JY, Savignoni A, Campana F, Dendale R, Fourquet A, Bollet MA.

Eur J Cancer. 2011 Jan;47(1):65-73. doi: 10.1016/j.ejca.2010.08.013. Epub 2010 Sep 16.

​

Prognostic factors for local recurrence following breast-conserving treatment in young women.

Bollet MA, Kirova YM, Fourquet A, de Cremoux P, Reyal F.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1215-27. doi: 10.1586/era.10.67. Review.

​

Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Mégnin-Chanet F, Bollet MA, Hall J.

Cell Mol Life Sci. 2010 Nov;67(21):3649-62. doi: 10.1007/s00018-010-0490-8. Epub 2010 Aug 20. Review.

PMID: 20725763 [PubMed - indexed for MEDLINE] Free PMC Article

 

Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Letouzé E, Allory Y, Bollet MA, Radvanyi F, Guyon F.

Genome Biol. 2010;11(7):R76. doi: 10.1186/gb-2010-11-7-r76. Epub 2010 Jul 22.

​

Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?

Daveau C, Savignoni A, Abrous-Anane S, Pierga JY, Reyal F, Gautier C, Kirova YM, Dendale R, Campana F, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1452-9. doi: 10.1016/j.ijrobp.2010.01.003. Epub 2010 Jun 3.

​

The impact of the loco-regional treatment in elderly breast cancer patients: hypo-fractionated exclusive radiotherapy, single institution long-term results.

Chargari C, Kirova YM, Laki F, Savignoni A, Dorval T, Dendale R, Bollet MA, Fourquet A, Campana F; Institut Curie Breast Cancer Study Group.

Breast. 2010 Oct;19(5):413-6. doi: 10.1016/j.breast.2010.04.004. Epub 2010 May 18.

​

Management of inflammatory breast cancer after neoadjuvant chemotherapy.

Abrous-Anane S, Savignoni A, Daveau C, Pierga JY, Gautier C, Reyal F, Dendale R, Campana F, Kirova YM, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1055-63. doi: 10.1016/j.ijrobp.2009.12.009. Epub 2010 May 17.

​

Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients.

Kirova YM, Castro Pena P, Hijal T, Fournier-Bidoz N, Laki F, Sigal-Zafrani B, Dendale R, Bollet MA, Campana F, Fourquet A.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1352-5. doi: 10.1016/j.ijrobp.2009.10.049. Epub 2010 Apr 8.

​

Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy.

Hijal T, Fournier-Bidoz N, Castro-Pena P, Kirova YM, Zefkili S, Bollet MA, Dendale R, Campana F, Fourquet A.

Radiother Oncol. 2010 Mar;94(3):300-6. doi: 10.1016/j.radonc.2009.12.043. Epub 2010 Feb 18.

 

Delayed reaction after adjuvant whole breast radiotherapy at the dose of 42.9 Gy in 13 fractions over 5 weeks: the need for rapid post irradiation clinical assessment and who are the patients at risk?

Kirova YM, Botti M, Campana F, Dendale R, Zervoudis S, Kyrias G, Bollet MA, Fourquet A.

J BUON. 2009 Oct-Dec;14(4):729-30. No abstract available.

​

Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients.

Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P, Ferreyra-Dillon R, Bollet C, Quintin E, Dieude P, Palazzo E, Wattiaux MJ, Kahn MF, Meyer O, Chollet-Martin S, Hayem G.

J Rheumatol. 2010 Mar;37(3):639-43. doi: 10.3899/jrheum.090863. Epub 2010 Jan 28.

​

Technique alternatives for breast radiation oncology: Conventional radiation therapy to tomotherapy.

Fournier-Bidoz N, Kirova Y, Campana F, El Barouky J, Zefkili S, Dendale R, Bollet MA, Mazal A, Fourquet A.

J Med Phys. 2009 Jul;34(3):149-52. doi: 10.4103/0971-6203.54849.

​

Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy.

Kirova YM, Castro Pena P, Dendale R, Servois V, Bollet MA, Fournier-Bidoz N, Campana F, Fourquet A.

Br J Radiol. 2010 Aug;83(992):683-6. doi: 10.1259/bjr/28834220. Epub 2009 Dec 17.

​

Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, Degeorges A, Sigal-Zafrani B, Almouzni G, Cottu P, Salmon R, Servant N, Fourquet A, de Cremoux P.

Breast Cancer Res. 2009;11(4):R54. doi: 10.1186/bcr2343. Epub 2009 Jul 28.

​

[Definition of nodal volumes in breast cancer treatment and segmentation guidelines].

Kirova YM, Castro Pena P, Dendale R, Campana F, Bollet MA, Fournier-Bidoz N, Fourquet A.

J Radiol. 2009 Jun;90(6):747-51. French.

​

[Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie].

Haberer S, Laé M, Seegers V, Pierga JY, Salmon R, Kirova YM, Dendale R, Campana F, Reyal F, Miranda O, Fourquet A, Bollet MA.

Cancer Radiother. 2009 Jul;13(4):305-12. doi: 10.1016/j.canrad.2009.05.001. Epub 2009 Jun 12. French.

​

[Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].

Kirova YM, Caussa L, Granger B, Savignoni A, Dendale R, Campana F, Tournat H, Pierga JY, Fourquet A, Bollet MA.

Cancer Radiother. 2009 Jul;13(4):276-80. doi: 10.1016/j.canrad.2009.02.008. Epub 2009 May 17. French.

​

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, Fourquet A; Breast Cancer Study Group of the Institut Curie.

Anticancer Res. 2009 May;29(5):1475-82.

​

Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.

Monteau A, Sigal-Zafrani B, Kirova YM, Fourchotte V, Bollet MA, Vincent-Salomon A, Asselain B, Salmon RJ, Fourquet A.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1021-8. doi: 10.1016/j.ijrobp.2008.12.014. Epub 2009 Apr 20.

​

Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers.

Castro Pena P, Kirova YM, Campana F, Dendale R, Bollet MA, Fournier-Bidoz N, Fourquet A.

Br J Radiol. 2009 Jul;82(979):595-9. doi: 10.1259/bjr/96865511. Epub 2009 Mar 2.

​

Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy.

Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R, Bollet MA, Salmon RJ, Fourquet A; Institut Curie Breast Cancer Study Group.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):76-81. doi: 10.1016/j.ijrobp.2008.11.005. Epub 2009 Jan 23.

​

[Hypofractionated breast radiotherapy in 13 fractions, perfect tolerance or delayed early reaction? Prospective study of Curie Institute].

Botti M, Kirova YM, Dendale R, Savignoni A, Fromantin I, Gautier C, Bollet MA, Campana F, Fourquet A.

Cancer Radiother. 2009 Apr;13(2):92-6. doi: 10.1016/j.canrad.2008.11.009. Epub 2009 Jan 23. French.

​

[Shared responsibility for follow-up of breast cancer patients. Experience of the Institut Curie].

Chargari C, Kirova Y, Bollet M, Sigal-Zafrani B, Dendale R, Rizand P, de la Rochefordiere A, Fourquet A, Campana F.

Bull Cancer. 2008 Nov;95(11):1047-51. doi: 10.1684/bdc.2008.0746. French.

​

[Meta-analyses of the effects of radiotherapy in breast cancer: the ultimate evidence?].

Fourquet A, Kirova Y, Bollet MA, Tournat H, Dendale R, Campana F.

Cancer Radiother. 2008 Nov;12(6-7):554-8. doi: 10.1016/j.canrad.2008.08.279. Epub 2008 Oct 1. French.

​

The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?

Bauduceau O, Bollet MA, Pons P, Kirova YM, Fayolle M, Zervoudis S, Campana F.

J BUON. 2008 Apr-Jun;13(2):245-51.

​

How to boost the breast tumor bed? A multidisciplinary approach in eight steps.

Kirova YM, Fournier-Bidoz N, Servois V, Laki F, Pollet GA, Salmon R, Thomas A, Dendale R, Bollet MA, Campana F, Fourquet A.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):494-500. doi: 10.1016/j.ijrobp.2007.12.059. Epub 2008 Apr 18.

​

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.

Bollet MA, Savignoni A, Pierga JY, Lae M, Fourchotte V, Kirova YM, Dendale R, Campana F, Sigal-Zafrani B, Salmon R, Fourquet A, Vincent-Salomon A.

Br J Cancer. 2008 Feb 26;98(4):734-41. doi: 10.1038/sj.bjc.6604229. Epub 2008 Feb 5.

​

High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.

Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, De Rycke Y, Savignoni A, Rigaill G, Hupé P, Fourquet A, Sigal-Zafrani B, Barillot E, Thiery JP.

J Natl Cancer Inst. 2008 Jan 2;100(1):48-58. Epub 2007 Dec 25.

​

Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.

Bollet MA, Kirova YM, Antoni G, Pierga JY, Sigal-Zafrani B, Laki F, Campana F, Dendale R, Salmon R, Cottu P, Fourquet A.

Radiother Oncol. 2007 Dec;85(3):336-45. Epub 2007 Oct 29.

​

Are ipsilateral breast tumour invasive recurrences in young women more aggressive than their primary tumours?

Sigal-Zafrani B, Bollet MA, Antoni G, Savignoni A, Vincent-Salomon A, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A.

Br J Cancer. 2007 Oct 22;97(8):1046-52. Epub 2007 Sep 18.

​

Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy.

Kirova YM, Campana F, Fournier-Bidoz N, Stilhart A, Dendale R, Bollet MA, Fourquet A.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1139-44. Epub 2007 Aug 6.

​

Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study.

Bollet MA, Thibault F, Bouillon K, Meunier M, Sigal-Zafrani B, Savignoni A, Diéras V, Nos C, Salmon R, Fourquet A; Institut Curie Breast Cancer Study Group.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):13-8. Epub 2007 Apr 20.

​

Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.

Toledano AH, Bollet MA, Fourquet A, Azria D, Gligorov J, Garaud P, Serin D, Bosset JF, Miny-Buffet J, Favre A, LeFoch O, Calais G.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):66-72.

​

Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first.

Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A.

Radiother Oncol. 2007 Mar;82(3):272-80. Epub 2007 Feb 6. Erratum in: Radiother Oncol. 2007 May;83(2):215.

​

Demineralisation of permeable hydroxyapatite with alternating water and acidic buffer: scanning microradiographic study of effect of switching period.

Bollet-Quivogne FR, Anderson P, Dowker SE, Elliott JC.

Caries Res. 2007;41(2):152-60.

​

Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.

Bollet MA, Sigal-Zafrani B, Gambotti L, Extra JM, Meunier M, Nos C, Dendale R, Campana F, Kirova YM, Diéras V, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2006 Sep;42(14):2286-95. Epub 2006 Aug 8.

​

Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study.

Bollet MA, Campana F, Kirova YM, Dendale R, Saliou MG, Rosenwald JC, Fourquet A.

Br J Radiol. 2006 Oct;79(946):785-90. Epub 2006 Jul 5.

​

CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning.

Kirova YM, Servois V, Campana F, Dendale R, Bollet MA, Laki F, Fournier-Bidoz N, Fourquet A.

Radiother Oncol. 2006 Jun;79(3):310-5. Epub 2006 Jun 12.

​

Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study.

Bruna A, Gastelblum P, Thomas L, Chapet O, Bollet MA, Ardiet JM, Gérard JP, Peiffert D.

Radiother Oncol. 2006 Apr;79(1):75-9.

​

[Radiation-induced sarcomas after breast cancer: experience of Institute Curie and review of literature].

Kirova Y, Vilcoq JR, Asselain B, Sastre-Garau X, Campana F, Dendale R, Bollet M, Fourquet A.

Cancer Radiother. 2006 Feb-Mar;10(1-2):83-90. Epub 2005 Nov 21. Review. French.

​

[Comparison of classic simulation and virtual simulation in breast irradiation: prospective study on 14 patients].

Bauduceau O, Pons P, Campana F, Bollet M, Romero L, Fayolle M.

Cancer Radiother. 2005 Nov;9(6-7):402-10. Epub 2005 Oct 12. French.

​

Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons.

Noël G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, Ferrand R, Boisserie G, Beaudré A, Mazeron JJ, Habrand JL.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22.

​

Linac stereotactic radiosurgery: an effective and safe treatment for elderly patients with brain metastases.

Noel G, Bollet MA, Noel S, Feuvret L, Boisserie G, Tep B, Delattre JY, Baillet F, Ambroise Valery C, Cornu P, Mazeron JJ.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1555-61. Epub 2005 Jul 18.

​

Efficacy and morbidity of arc-therapy radiosurgery for cerebral arteriovenous malformations: a comparison with the natural history.

Bollet MA, Anxionnat R, Buchheit I, Bey P, Cordebar A, Jay N, Desandes E, Marchal C, Lapeyre M, Aletti P, Picard L.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1353-63. Review.

​

Postoperative brachytherapy alone and combined postoperative radiotherapy and brachytherapy boost for squamous cell carcinoma of the oral cavity, with positive or close margins.

Lapeyre M, Bollet MA, Racadot S, Geoffrois L, Kaminsky MC, Hoffstetter S, Dolivet G, Toussaint B, Luporsi E, Peiffert D.

Head Neck. 2004 Mar;26(3):216-23.

​

Can digitally reconstructed radiographs (DRRS) replace simulation films in prostate cancer conformal radiotherapy?

Bollet MA, McNair HA, Hansen VN, Norman A, O'Doherty U, Taylor H, Rose M, Mukherjee R, Huddart R.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1122-30.

​

Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone.

Lee YK, Bollet M, Charles-Edwards G, Flower MA, Leach MO, McNair H, Moore E, Rowbottom C, Webb S.

Radiother Oncol. 2003 Feb;66(2):203-16.

​

Cervical lymph node relapses of head-and-neck squamous cell carcinoma: is brachytherapy a therapeutic option?

Bollet MA, Lapeyre M, Marchal C, Hoffstetter S, Peiffert D, Cornes PG, Luporsi E, Bey P.

Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1305-12.

 

[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey].

Spielmann M, Dalenc F, Pointreau Y, Azria D, Classe JM, Dromain C, Facchini T, Gonçalves A, Liegeois P, Namer M, Pivot X, Vincent-Salomon A.

Bull Cancer. 2016 Feb;103(2):154-63. doi: 10.1016/j.bulcan.2015.10.007. Epub 2015 Dec 2. French.

​

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2015 Oct 3;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.

​

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roché H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M.

Future Oncol. 2015;11(16):2283-97. doi: 10.2217/fon.15.102.

​

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.

​

Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.

Lopez C, Charles C, Rouby P, Boinon D, Laurent S, Rey A, Spielmann M, Dauchy S.

Support Care Cancer. 2015 Dec;23(12):3581-8. doi: 10.1007/s00520-015-2722-9. Epub 2015 Apr 17.

​

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

Ladoire S, Dalban C, Roché H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F.

Eur J Cancer. 2014 Feb;50(3):506-16. doi: 10.1016/j.ejca.2013.11.013. Epub 2013 Dec 4.

​

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

Filleron T, Md FD, Kramar A, Spielmann M, Levy C, Fumoleau P, Canon JL, Martin AL, Roché H.

Bull Cancer. 2013 Jul-Aug;100(7-8):22-9. doi: 10.1684/bdc.2013.1791.

​

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.

Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.

Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587-x. Epub 2013 Jun 19.

​

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer.

Kader YA, Spielmann M, El-Nahas T, Sakr A, Metwally H.

Breast Cancer (Dove Med Press). 2013 Jun 17;5:37-42. doi: 10.2147/BCTT.S44728. eCollection 2013.

​

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

Filleron T, Kramar A, Dalenc F, Spielmann M, Fumoleau P, Kerbrat P, Martin AL, Roché H.

Bull Cancer. 2012 Jun;99(6):E64-74. doi: 10.1684/bdc.2012.1592.

​

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group.

Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18.

​

3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity.

Dzhugashvili M, Tournay E, Pichenot C, Dunant A, Pessoa E, Khallel A, Gouy S, Uzan C, Garbay JR, Rimareix F, Spielmann M, Vielh P, Marsiglia H, Bourgier C.

Radiat Oncol. 2009 Dec 31;4:70. doi: 10.1186/1748-717X-4-70.

​

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M.

Breast Cancer Res Treat. 2010 Jul;122(2):429-37. doi: 10.1007/s10549-010-0939-3. Epub 2010 May 18.

​

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M.

Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.

​

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A.

Eur J Cancer. 2011 Mar;47(4):515-9. doi: 10.1016/j.ejca.2010.11.025. Epub 2011 Jan 19.

​

Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.

Bourgier C, Pessoa EL, Dunant A, Heymann S, Spielmann M, Uzan C, Mathieu MC, Arriagada R, Marsiglia H.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):690-5. doi: 10.1016/j.ijrobp.2010.11.040. Epub 2011 Jan 27.

​

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M.

Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. French.

​

Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study.

Spielmann M, Luporsi E, Ray-Coquard I, de Botton S, Azria D, Lasocki S, Lafuma A, Mahi L, Deray G, Bugat R.

Eur J Cancer. 2012 Jan;48(1):101-7. doi: 10.1016/j.ejca.2011.09.011. Epub 2011 Oct 31.

​

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP.

Breast Cancer Res Treat. 2012 Apr;132(3):895-915. doi: 10.1007/s10549-011-1837-z. Epub 2011 Nov 3. Review.

​

Phase II trial of 3D-conformal accelerated partial breast irradiation: lessons learned from patients and physicians' evaluation.

Azoury F, Heymann S, Acevedo C, Spielmann M, Vielh P, Garbay JR, Taghian AG, Marsiglia H, Bourgier C.

Radiother Oncol. 2012 May;103(2):193-8. doi: 10.1016/j.radonc.2012.03.019. Epub 2012 Apr 20.

​

CXCR4 expression in early breast cancer and risk of distant recurrence.